Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paliperidone Palmitate

FDA-approved product (suspension, extended release, intramuscular), marketed as Erzofri, Invega Hafyera, Invega Sustenna and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Paliperidone Palmitate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paliperidone Palmitate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paliperidone Palmitate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia

    NCT00697658 · start 2008-03

    Registered record
    Registry ID
    NCT00697658
    Conditions
    Schizophrenia
    Interventions
    Paliperidone ER
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-03
    Completion
    2009-11
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone ER
    PhaseNot recorded
    Registry statusCompleted

  • Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia

    NCT01724359 · start 2008-02

    Registered record
    Registry ID
    NCT01724359
    Conditions
    Schizophrenia
    Interventions
    Paliperidone ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-02
    Completion
    2009-11
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone ER
    PhasePhase 4
    Registry statusCompleted

  • Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics

    NCT03730857 · start 2008-01

    Registered record
    Registry ID
    NCT03730857
    Conditions
    Schizophrenia
    Interventions
    Olanzapine; risperidone; Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-12
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionOlanzapine; risperidone; Paliperidone
    PhasePhase 1
    Registry statusCompleted

  • A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia

    NCT01606228 · start 2007-12

    Registered record
    Registry ID
    NCT01606228
    Conditions
    Schizophrenia
    Interventions
    Paliperidone ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-12
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone ER
    PhasePhase 3
    Registry statusCompleted

  • Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder

    NCT00592358 · start 2007-11

    Registered record
    Registry ID
    NCT00592358
    Conditions
    Pediatric Bipolar Disorder
    Interventions
    paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-11
    Completion
    2009-12
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Bipolar Disorder
    Interventionpaliperidone
    PhasePhase 4
    Registry statusTerminated

  • Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

    NCT00535132 · start 2007-10

    Registered record
    Registry ID
    NCT00535132
    Conditions
    Schizophrenia
    Interventions
    Oral Risperidone; Paliperidone ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-10
    Completion
    2008-07
    Enrolment
    201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionOral Risperidone; Paliperidone ER
    PhasePhase 4
    Registry statusCompleted

  • Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder

    NCT00632229 · start 2007-10

    Registered record
    Registry ID
    NCT00632229
    Conditions
    Obsessive-Compulsive Disorder
    Interventions
    Paliperidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-10
    Completion
    2013-09
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObsessive-Compulsive Disorder
    InterventionPaliperidone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia

    NCT00473434 · start 2007-04

    Registered record
    Registry ID
    NCT00473434
    Conditions
    Schizophrenia
    Interventions
    Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-04
    Completion
    2009-08
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone
    PhasePhase 3
    Registry statusCompleted

  • A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR

    NCT00791193 · start 2007-03

    Registered record
    Registry ID
    NCT00791193
    Conditions
    Schizophrenia
    Interventions
    Paliperidone ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-03
    Completion
    2007-05
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone ER
    PhasePhase 1
    Registry statusCompleted

  • A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

    NCT01606254 · start 2007-01

    Registered record
    Registry ID
    NCT01606254
    Conditions
    Schizophrenia
    Interventions
    Paliperidone palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-01
    Completion
    2008-04
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone palmitate
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

    NCT00490971 · start 2006-05

    Registered record
    Registry ID
    NCT00490971
    Conditions
    Bipolar Disorder
    Interventions
    Olanzapine; Paliperidone ER; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-05
    Completion
    2010-04
    Enrolment
    768

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionOlanzapine; Paliperidone ER; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

    NCT00796081 · start 2006-01

    Registered record
    Registry ID
    NCT00796081
    Conditions
    Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorders
    Interventions
    ER OROS paliperidone, paliperidone ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-01
    Completion
    2006-08
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Schizophreniform Disorders
    InterventionER OROS paliperidone, paliperidone ER
    PhasePhase 1
    Registry statusCompleted

  • A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate

    NCT01110317 · start 2005-07

    Registered record
    Registry ID
    NCT01110317
    Conditions
    Schizophrenia
    Interventions
    paliperidone palmitate 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-07
    Completion
    2006-03
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionpaliperidone palmitate 100 mg
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

    NCT00111189 · start 2005-02

    Registered record
    Registry ID
    NCT00111189
    Conditions
    Schizophrenia
    Interventions
    Placebo; Paliperidone Palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-02
    Completion
    2008-02
    Enrolment
    414

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPlacebo; Paliperidone Palmitate
    PhasePhase 3
    Registry statusCompleted

  • A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia

    NCT00210717 · start 2005-02

    Registered record
    Registry ID
    NCT00210717
    Conditions
    Schizophrenia
    Interventions
    paliperidone palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-02
    Completion
    2007-04
    Enrolment
    748

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionpaliperidone palmitate
    PhasePhase 3
    Registry statusCompleted